Pooled analyses of both trials confirm that vericiguat reduces cardiovascular events and HF hospitalizations, particularly in patients with NT-proBNP ≤ 6000 pg/mL, demonstrating that patient selection is key to maximizing benefit. The gene discussed is NPPB; the disease is hydrops fetalis.